

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 27, 2025**

---

**APTOSE BIOSCIENCES INC.**

(Exact name of registrant as specified in its charter)

**Canada**  
(State or Other Jurisdiction of Incorporation)

**001-32001**  
(Commission File Number)

**98-1136802**  
(I.R.S. Employer Identification No.)

**66 Wellington Street West, Suite 5300  
TD Bank Tower, Box 48  
Toronto, Ontario M5K 1E6  
Canada**

(Address of Principal Executive Offices) (Zip Code)

**(647) 479-9828**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On May 27, 2025, Aptose Biosciences Inc., or the “Corporation,” held an Annual and Special Meeting of the shareholders of the Corporation (the “Meeting”). At the Meeting, shareholders voted in favor of all items of business, as indicated below:

***Proposal No. 1-Election of Directors***

The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2026 Annual General Meeting:

<u>Nominee</u>	<u>Votes For</u>	<u>% Votes For</u>	<u>Votes Against</u>	<u>%Votes Against</u>	<u>Broker Non-Votes</u>
Ms. Carol G. Ashe	1,055,169	97.80	23,724	2.20	398,903
Dr. Denis Burger	1,054,232	97.71	24,662	2.29	398,902
Dr. Erich Platzter	1,065,494	98.76	13,399	1.24	398,903
Dr. William G. Rice	1,053,959	97.69	24,935	2.31	398,902
Dr. Mark D. Vincent	1,054,474	97.74	24,420	2.26	398,902
Mr. Warren Whitehead	1,065,452	98.75	13,442	1.25	398,902
Dr. Bernd Seizinger	1,065,504	98.76	13,389	1.24	398,903

***Proposal No. 2 – Appointment of Independent Registered Public Accounting Firm***

The Corporation’s shareholders voted to approve the appointment of an independent registered public accounting firm of the Corporation for the fiscal year ended December 31, 2025.

<u>Votes For</u>	<u>% Votes For</u>	<u>Vote Against</u>	<u>% Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
1,431,578	96.87	37,824	2.56	8,393	1

***Proposal No. 3 – Compensation of Named Executive Officers***

The Corporation’s shareholders voted to approve a non-binding resolution to approve the compensation paid to the Corporation’s named executive officers.

<u>Votes For</u>	<u>% Votes For</u>	<u>Vote Against</u>	<u>% Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
845,725	78.58	36,973	3.44	193,559	401,535

***Proposal No. 4 – Amendment to 2021 Stock Incentive Plan***

The Corporation’s shareholders voted to approve an amendment to the Corporation’s 2021 stock incentive plan to increase the number of common shares reserved for issuance thereunder by 458,126 common shares.

<u>Votes For</u>	<u>% Votes For</u>	<u>Vote Against</u>	<u>% Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
1,028,769	95.59	46,306	4.30	1,188	401,533

***Proposal No. 5 – Reverse Stock Split***

The shareholders approved an amendment to the Corporation’s Articles of Incorporation, as amended, to, at the discretion of the board of directors (the “Board”), effect a reverse stock split at a ratio between 2-to-1 and 20-to-1, with the ratio within such range to be determined at the discretion of the Board, based on the votes listed below:

<u>Votes For</u>	<u>% Votes For</u>	<u>Vote Against</u>	<u>% Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
1,267,992	87.25	178,518	12.28	6,725	24,561

***Proposal No. 6 – Meeting Adjournments***

The Corporation’s shareholders voted to approve a resolution permitting one or more adjournments of the meeting, if necessary or appropriate, if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes at the time of the meeting to approve Proposals No. 2, 4, and 5.

<u>Votes For</u>	<u>% Votes For</u>	<u>Vote Against</u>	<u>% Votes Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
1,054,192	97.71	24,584	2.28	118	398,902

**Item 7.01. Regulation FD Disclosure.**

On May 27, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.****Exhibit No.    Description of Exhibit**

<a href="#">99.1</a>	<a href="#">Press Release dated May 27, 2025</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Aptose Biosciences Inc.**

Date: May 28, 2025

By: /s/ William G. Rice, Ph.D. \_\_\_\_\_

William G. Rice, Ph.D.

Chairman, President, and Chief Executive Officer

## Aptose Announces Results from Annual and Special Meeting of Shareholders

SAN DIEGO and TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspentinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced the voting results from the Company's annual and special meeting of shareholders held today, May 27, 2025 (the "Meeting"). A total of 1,477,794 common shares of the Company, representing 57.90% of the common shares of the Company entitled to be voted, were voted by shareholders present or represented by proxy at the Meeting.

The Company is pleased to announce that all of the nominees listed in the proxy statement dated April 28, 2025 (the "Proxy Statement"), were re-elected as Directors. The results of the vote are provided below:

Nominee	Votes For	% Votes For	Votes Against	% Votes Against
Ms. Carol G. Ashe	1,055,169	97.80	23,724	2.20
Dr. Denis Burger	1,054,232	97.71	24,662	2.29
Dr. Erich Platzer	1,065,494	98.76	13,399	1.24
Dr. William G. Rice	1,053,959	97.69	24,935	2.31
Dr. Mark D. Vincent	1,054,474	97.74	24,420	2.26
Mr. Warren Whitehead	1,065,452	98.75	13,442	1.25
Dr. Bernd R. Seizinger	1,065,504	98.76	13,389	1.24

Aptose shareholders also voted in favor of the following matters:

- an advisory (non-binding) resolution on the compensation of the Corporation's named executive officers, as more particularly described in the Proxy Statement;
- a resolution, the full text of which is set forth in the Proxy Statement, approving amendments to the Corporation's 2021 stock incentive plan to increase the number of common shares reserved for issuance thereunder (the "Stock Incentive Plan Amendment Resolution");
- a resolution, the full text of which is set forth in the Proxy Statement, approving the adoption of an amendment to the Corporation's articles to effect a reverse stock split of the Company's outstanding common shares at a ratio in the range of 1-for-2 to 1-for-20, to be effected at a ratio and date as determined by the board of directors of Aptose (the "Reverse Split Proposal"); and
- a resolution, the full text of which is set forth in the Proxy Statement, approving one or more adjournments of the Meeting, if necessary or appropriate, if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes at the time of the Meeting to approve the Stock Incentive Plan Amendment Resolution or the Reverse Split Proposal and to permit the Corporation to complete the search for a successor auditor to KPMG LLP.

The Company has adjourned the Meeting to a later date and time to permit the Company to complete its search for a successor auditor to KPMG LLP. Once the new meeting date is determined, Aptose will issue a press release with the details and provide shareholders with information about the proposed new independent auditor. At the reconvened meeting, shareholders will be asked to vote on the appointment of the successor auditor and the authorization of the board of directors to set such auditor's remuneration.

Please refer to the Company's Proxy Statement available on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) or EDGAR [www.sec.gov](http://www.sec.gov) for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR+ and EDGAR.

### About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company's lead clinical-stage compound tuspentinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit [www.apptose.com](http://www.apptose.com).

### Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements regarding the Company's expectations with respect to retaining a new auditor, including further communication regarding the reconvention of the Meeting, expectations with respect to effecting the Reverse Split Proposal and other statements including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential" and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include risks detailed from time-to-time in our

ongoing current reports, quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

**For further information, please contact:**

Aptose Biosciences Inc.

Susan Pietropaolo

Corporate Communications & Investor Relations

201-923-2049

[spietropaolo@aptose.com](mailto:spietropaolo@aptose.com)